Edison Investment Research - Collplant Holdings Ltd (CLGN) CollPlant Holdings - Enters into licensing and commercialisation agreement

Report

Edison Investment Research

Maxim Jacobs

CollPlant Holdings - Enters into licensing and commercialisation agreement

In late October 2018, CollPlant and United Therapeutics (NASDAQ: UTHR) announced a licensing, development and commercialisation agreement for 3D bioprinted lung transplants using rhCollagen-based BioInk. This news follows the United Therapeuticsâ€™ Science Day in September, where its founder and CEO presented the companyâ€™s R&D using CollPlantâ€™s rhCollagen to 3D bioprint lung scaffolds. This co-development agreement further validates CollPlantâ€™s technology.

29/10/2018 5 EN

Underlying

Collplant Holdings Ltd

CollPlant Holdings is a biotechnology medical device company based in Israel. Co. is focused on advancing regenerative medicine by utilizing its proprietary processing technologies for human collagen and other recombinant proteins. Co. is engaged in developing a substantial range of biomaterials-based products applicable in multiple medical markets, including orthopaedics, wound management, cardiology and general surgery. In addition to virgin collagen, Co. also developes a family of products that offers a range of scaffolds. including sheets, sponges, gels, meshes, microsphere and compounds. Co. also plans to offer solutions for soft and hard tissue repair in diverse applications.

See profile

IL0004960188 Israel

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Maxim Jacobs

Other Reports on these Companies

Edison Investment Research

CollPlant Holdings - Ongoing third-party interest in BioInk

CollPlant demonstrated another productive quarter with a 209% increase in reported revenue over the same period in 2017, mainly attributed to sales of its BioInk product in the US and its Vergenix product brands, primarily its VergenixSTR for tendinopathy, in Europe. The rhCollagen-based BioInk continues to demonstrate that it is a strategic area of development for CollPlant with repeat sales to third parties.

October 3, 2018 October 3, 2018 4 EN

Edison Investment Research

CollPlant Holdings - A productive year to date

The year to date has been highly productive for CollPlant. It has completed a new production facility in Rehovot to support its increased commercial efforts. These include both its BioInk product for 3D bioprinting of organs and tissue, as well as VergenixFG and VergenixSTR for wound care and tendinopathy respectively, which are expanding operations in Europe. In addition, the company has announced its intention to de-list from TASE to trade exclusively on NASDAQ.

May 30, 2018 May 30, 2018 4 EN

International Public Partnerships - Consistently and responsibly delivering

International Public Partnerships’ (INPP’s) FY23 results show that it continues to deliver consistent and predictable returns for investors, while delivering environmental and social benefits for the individuals and communities that are served by its assets. Despite this strong performance and a substantial need for private infrastructure funding, the macroeconomic environment has weighed on INPP’s share price, in common with the wider sector. Regardless, attractive returns are available from the existing portfolio with opportunities for further enhancement.

15h / 34m 15h / 34m 1 EN

Kate Heseltine

Kate Heseltine

Portobello SpA - Focus back on the operations

Portobello’s FY23 results demonstrate the primary effects of the out-of-court settlement with respect to VAT and direct taxes (a higher year-end net debt position) and the secondary effects, such as disruption to its trading activities due to management’s focus on cash generation and the company’s inability to trade as previously expected. Following the period end, two capital raises totalling €12.6m, including €3.8m by three of the executive management team, from a maximum mandated amount of €20m, have improved the company’s financial position. The requirement to improve the balance sheet fur...

16h / 18m 16h / 18m 1 EN

Kate Heseltine

Kate Heseltine

Intralot - Focus on business development in FY24

Intralot enjoyed good underlying trends in performance in FY23 with encouraging trends in its main countries of focus and further progress on profitability. The much-improved balance sheet and extension of debt maturities mean management can focus on the significant business development opportunities available in FY24 and beyond. The share price looks attractive in the absence of potential new contract wins, which could be materially enhancing to the valuation.

21h / 32m 21h / 32m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

CollPlant Holdings - Enters into licensing and commercialisation agreement

CollPlant Holdings - Ongoing third-party interest in BioInk

CollPlant Holdings - A productive year to date

International Public Partnerships - Consistently and responsibly delivering

Portobello SpA - Focus back on the operations

Intralot - Focus on business development in FY24

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe